Drug Type Bispecific antibody |
Synonyms UBB 2048, UBB2048, UBX-2048 + [1] |
Target |
Action antagonists, inhibitors |
Mechanism Tie-2 antagonists(TEK receptor tyrosine kinase antagonists), VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Retinal Vascular Disorder | Preclinical | United States | - |